The IgA nephropathy clinic nurse’s communication challenge
IgA nephropathy — also called Berger’s disease — is the most common primary glomerulonephritis in the world and the most common cause of primary glomerular disease in US adults under fifty. It produces kidney damage through a mechanism that is largely invisible between episodes: galactose-deficient IgA1 produced by mucosal plasmablasts in the tonsils and intestinal Peyer’s patches forms immune complexes with circulating auto-antibodies, deposits in the glomerular mesangium, activates complement and mesangial inflammatory signaling, drives mesangial matrix expansion and tubulointerstitial fibrosis, and produces progressive GFR decline over decades. The primary visible symptom — gross hematuria that turns the urine red or brown during upper respiratory infections — is the acute inflammatory marker of the disease, not the primary driver of long-term nephron loss. Between hematuria episodes, the same immune complex deposition continues at a lower rate, silently, without any symptom the patient can detect. This structure creates a recurring adherence challenge: patients monitor their disease through visible signals (hematuria, creatinine, proteinuria) and draw conclusions about treatment necessity from those visible signals, while the actual mechanism driving progressive nephron loss operates continuously at a level that is invisible to those monitors.
The communication failures in the IgA nephropathy clinic cluster around three structural misunderstandings. The first is the equation of creatinine normalization with disease resolution: a patient on RAAS blockade whose creatinine falls from 1.2 to 1.0 milligrams per deciliter interprets this improvement as evidence that the kidney has healed and that the medications protecting it against future damage are no longer needed, not understanding that RAAS blockade provides ongoing protection against intraglomerular hypertension and TGF-beta1-driven fibrosis through mechanisms that are active every day the drug is taken and inactive every day it is not. The second is the equation of hematuria resolution with disease resolution: a patient on targeted-release budesonide who has not had a single gross hematuria episode in six months concludes that the disease is gone, not understanding that the budesonide was reducing acute mucosal IgA1 surges while the chronic background Gd-IgA1 production in the intestine continues producing ongoing mesangial deposition. The third is the equation of proteinuria reduction with disease resolution: a patient on dapagliflozin whose proteinuria falls from 0.9 to 0.4 grams per day concludes that the medication has accomplished its purpose, not understanding that proteinuria is a hemodynamic surrogate and that SGLT2 inhibition’s mechanisms of nephron protection — intraglomerular hyperfiltration correction, tubular NF-kB suppression, NLRP3 inflammasome reduction — are all independent of the proteinuria level and active only while the drug is present. All three errors follow the template: visible improvement is interpreted as elimination of the driving pathological process, and treatment is stopped because the disease appears gone when in fact only a downstream surrogate of a continuous process has improved.
Three conversations from the IgA nephropathy clinic:
Scenario 1: Ricardo Mendoza-García — 32 years old, Houston, Texas
Ricardo Mendoza-García was a structural engineer in Houston who had been referred to nephrology after an occupational health screening found a urine protein-to-creatinine ratio of 0.85 grams per gram and a serum creatinine of 1.2 milligrams per deciliter (eGFR 68 ml/min/1.73m²) on a routine pre-employment physical. He had no history of kidney disease, no hypertension, no diabetes. He recalled having three episodes over the past four years of brief red-brown urine lasting one to two days during bad sore throats, which he had attributed to dehydration. Ultrasound showed normal kidney size and architecture bilaterally. Complement levels were normal. An ANCA, anti-GBM, anti-dsDNA, and hepatitis panel were negative. The nephrologist recommended kidney biopsy. Light microscopy showed mesangial hypercellularity and matrix expansion in approximately sixty percent of glomeruli. Immunofluorescence showed diffuse mesangial IgA deposits with co-deposits of IgG, C3, and C1q. Electron microscopy confirmed predominantly mesangial electron-dense deposits. Oxford classification: M1 (mesangial hypercellularity score >0.5) E1 (endocapillary hypercellularity present, in fewer than half the glomeruli) S0 (no segmental sclerosis) T0 (no tubular atrophy or interstitial fibrosis >25%) C0 (no crescents).
Ricardo’s nephrologist discussed the biopsy findings with him and explained that the current pathological picture showed active mesangial immune complex disease with early endocapillary involvement but no permanent scarring yet — a picture with meaningful potential for slowing progression with treatment. She started dual RAAS blockade: lisinopril twenty milligrams daily and losartan fifty milligrams daily, at the maximum tolerated doses based on a brief trial period. Ricardo’s initial blood pressure at diagnosis was 124/78 millimeters of mercury. He was advised that the dual RAAS blockade was being used for its kidney-protective mechanisms beyond blood pressure control and that his blood pressure targets on the medications would be systolic under 125. He was also counseled on salt restriction and started on fish oil supplementation. Follow-up urine protein-to-creatinine ratios at two months, four months, and six months showed 0.68, 0.48, and 0.32 grams per gram respectively. Creatinine at eight months was 1.0 mg/dL (eGFR 80). Ricardo called this “the first time in years the number looked normal.”
At the nine-month visit, Ricardo told his clinic nurse, Elena Morales-Cisneros, that he had stopped both the lisinopril and losartan approximately three weeks earlier. His reasoning was presented straightforwardly: the creatinine was now normal, the protein in the urine had fallen to one-third of what it had been at diagnosis, he felt well, he was thirty-two years old and did not want to be on medications permanently for a kidney disease that appeared to have resolved, and he was concerned about long-term effects of dual RAAS blockade on kidney function if continued for years. He had read online that ACE inhibitors could cause creatinine rises and was concerned about taking a medication that “affects the kidneys” when his kidneys appeared to be recovering.
Nurse Morales-Cisneros recognized the internal coherence of Ricardo’s reasoning and the specific misconceptions embedded in it. The online information about ACE inhibitor creatinine effects was not wrong — RAAS blockade does produce a modest initial creatinine rise that reflects the hemodynamic mechanism — but it had been misapplied to a context where that rise represents the medication working, not damaging. She asked if she could explain specifically what the RAAS blockade was doing for Ricardo’s kidneys that the creatinine number could not capture, before Ricardo talked with Dr. Lara-Espinoza.
Morales-Cisneros began with the mechanism of kidney damage in IgA nephropathy. The core problem, she explained, was not Ricardo’s blood pressure — which was normal at diagnosis and remained well-controlled on the medications. The core problem was what was happening inside the individual kidney filters, called glomeruli, where immune protein deposits were triggering inflammation and scarring. In IgA nephropathy, abnormal IgA protein produced in the tonsils and intestine formed complexes with other immune proteins and deposited in the mesangium — the central supporting tissue of each glomerulus. These deposits activated inflammatory signaling that gradually damaged the glomerular filtering membrane, produced scarring in the mesangium, and drove the kidney’s support tissue between glomeruli to become fibrotic over years. This process was ongoing in Ricardo’s case right now, today, regardless of what the creatinine number showed. The biopsy had shown active mesangial disease eight months ago, and the underlying cause of that disease — the production of abnormal IgA1 in his mucosal immune system — had not been resolved by any of the treatments he was taking.
The RAAS medications — lisinopril and losartan — were providing kidney protection through three mechanisms that were all completely separate from the creatinine number. The first mechanism was reducing pressure inside the kidney filters. In a kidney with active IgA nephropathy, the immune complex deposits damaged individual glomeruli over time, reducing the total number of functioning filters. The remaining filters compensated by allowing more blood through each one — a state called glomerular hypertension. This high pressure inside the filters damaged their delicate filtering membranes just like water pressure damages pipes over time. The RAAS system — particularly angiotensin II — was one of the regulators of this intraglomerular pressure, because angiotensin II constricted the small vessel leading blood out of each glomerulus, keeping the pressure inside the filter high. ACE inhibitors and ARBs blocked this angiotensin II effect, reducing the pressure inside each remaining filter and protecting those filters from pressure-driven mechanical damage. Ricardo’s creatinine being 1.0 did not mean his intraglomerular pressure was normal; it meant he still had enough functioning nephrons to produce a creatinine reading in the normal range. The intraglomerular pressure was being controlled by the medications. Without them, the pressure inside the remaining filters would increase within days.
The second mechanism, Morales-Cisneros continued, was chemical. Angiotensin II had direct effects on the mesangial cells in the glomeruli beyond its pressure effects — it directly stimulated those cells to produce TGF-beta1, a chemical signal that drove scarring and fibrosis in the kidney. ACE inhibitors and ARBs reduced the amount of angiotensin II reaching the mesangial cells, reducing this TGF-beta1 production signal independent of blood pressure. Reducing TGF-beta1 production from the mesangium was important because TGF-beta1 was the central driver of the fibrosis in both the mesangium itself and the tubulointerstitial tissue — and it was the tubulointerstitial fibrosis that most strongly predicted long-term progression to kidney failure in IgA nephropathy. This mechanism operated at normal blood pressure because angiotensin II production and receptor signaling occurred in mesangial cells locally in the kidney, not just in response to systemic blood pressure.
The third mechanism was protecting the tubular cells from protein-driven injury. When the glomerular filter was damaged by IgA immune complex deposits, it allowed protein to leak into the kidney tubule where it would normally not be present. Tubular cells exposed to leaked protein responded with inflammatory signaling that drove scarring between the glomeruli. The RAAS medications reduced both the pressure and the direct angiotensin II effects that were driving this protein leak — which was why his urine protein had fallen from 0.85 to 0.32 grams per gram over eight months. That fall in protein was not the disease resolving; it was the medications actively reducing protein leak through both hemodynamic and chemical mechanisms, and protecting the tubular cells from protein-driven inflammatory injury. Stop the medications, and protein in the urine would return toward pre-treatment levels within weeks, and the tubular injury cascade would resume.
Ricardo asked the central question: “¿Entonces la creatinina normal no significa que el riñón se curó?” (So the normal creatinine doesn’t mean the kidney was cured?) Morales-Cisneros answered directly: “No. La creatinina normal significa que todavía le queda suficiente riñón funcionando para que el cuerpo lo maneje bien. Los medicamentos están protegiendo lo que le queda. Sin ellos, la presión dentro de los filtros sube, la proteína en la orina vuelve a subir, y ese proceso va perdiendo más filtros poco a poco, aunque no lo sienta. La creatinina solo sube cuando ya se perdió bastante — puede parecer estable durante años mientras el daño va avanzando por debajo.” (No. The normal creatinine means that you still have enough functioning kidney for the body to manage it well. The medications are protecting what you have left. Without them, the pressure inside the filters rises, the protein in the urine rises again, and that process loses more filters little by little, even though you don’t feel it. Creatinine only rises when enough has already been lost — it can look stable for years while damage advances underneath.) Ricardo agreed to restart both medications. At his twelve-month visit, three months after restarting, proteinuria was back at 0.30 grams per gram and creatinine was 0.98 mg/dL — essentially identical to the pre-cessation values. The brief cessation had not produced irreversible damage in three weeks, but the trajectory had been recaptured before it could.
Scenario 2: Sofía Herrera-Cisneros — 28 years old, San Antonio, Texas
Sofía Herrera-Cisneros was a pediatric occupational therapist in San Antonio who had been referred to nephrology after three emergency department visits over fourteen months for gross hematuria — urine that turned dark brown and tea-colored for one to two days, each time following pharyngitis by approximately twenty-four to forty-eight hours. Her primary care physician had initially reassured her after the first two episodes that brief hematuria after throat infections was usually benign, but the third episode prompted an urgent nephrology referral. A kidney biopsy showed IgA nephropathy with Oxford classification M1 E0 S0 T0 C0 — mesangial hypercellularity in more than half the glomeruli, no endocapillary lesions, no sclerosis, no tubular atrophy, no crescents. Her creatinine was 0.9 milligrams per deciliter and eGFR was 85 ml/min/1.73m² at diagnosis. Urine protein-to-creatinine ratio was 0.28 grams per gram. Serum IgA was elevated at 410 mg/dL (normal under 400). Blood pressure was 118/72 millimeters of mercury.
Sofía’s nephrologist discussed treatment options with her. Her proteinuria was below the standard threshold for full RAAS blockade benefit (less than 0.5 grams per gram), and her kidney function was currently well preserved. However, the Oxford M1 biopsy lesion and recurrent synpharyngeal hematuria in a twenty-eight-year-old woman with a decades-long projected kidney risk window created a compelling argument for disease-modifying treatment. She was started on targeted-release budesonide (Nefecon four milligrams twice daily — the formulation designed to release in the terminal ileum at the Peyer’s patch sites of IgA1 production) in addition to a low-dose RAAS inhibitor (lisinopril five milligrams daily). She was counseled extensively on how the targeted-release budesonide worked: it was delivered to the terminal ileum specifically to reduce the galactose-deficient IgA1 that the intestinal Peyer’s patches produced as part of the chronic background disease process, separate from the acute tonsillar responses that produced the synpharyngeal hematuria episodes.
The response on treatment was gratifying. Her first year on targeted-release budesonide was her first year without a single gross hematuria episode: no red or brown urine, no emergency department visits for hematuria, no episodes triggered by the two respiratory infections she did have during that year. At the eight-month visit, she reported that a minor URI two weeks earlier had caused her anxiety because of her history — she had monitored her urine at every void for three days — and no hematuria had occurred. She came to the visit feeling, as she told nurse Patricia García-Ramos, “like the disease is gone.” She had been reading about IgA nephropathy in patient forums and had seen other patients describe how their hematuria resolved on treatment and how they eventually came off medications. She asked nurse García-Ramos directly whether, given that she had been entirely free of hematuria for eight months, she might be a candidate to stop the budesonide.
Nurse García-Ramos recognized the significance of this moment. Eight months without a single hematuria episode represented a real and meaningful clinical improvement and was one of the goals of treatment. But the absence of hematuria was not the only goal, and it was not the same as disease resolution. She asked Sofía if she could walk through the mechanism of what the budesonide was doing in her body and why stopping it would restart a disease process she could not see or feel.
García-Ramos began with the distinction between what caused the gross hematuria episodes and what caused the long-term kidney damage. The hematuria episodes, she explained, were dramatic but not the most dangerous part of IgA nephropathy. They occurred because of a specific mechanism: when Sofía had a throat infection, her tonsillar lymphoid tissue was activated by the infecting bacteria or virus, and as part of the immune response, tonsillar B lymphocytes produced large amounts of IgA antibodies to fight the infection. In patients with IgA nephropathy, the IgA produced in this acute response was structurally abnormal — it was missing certain sugar attachments on its hinge region, a type of protein called galactose-deficient IgA1. This abnormal IgA formed complexes with other antibodies in the blood and deposited rapidly in large amounts in the glomerular mesangium. This acute heavy deposition activated complement and inflammation in the glomeruli severe enough to rupture blood vessels and produce the visible red-brown hematuria. This was why the hematuria appeared one to two days after the sore throat started — it tracked the acute tonsillar IgA burst directly.
But between throat infections, when the tonsils were not acutely activated, the same abnormal IgA1 was being produced continuously at a lower level by a different source: the Peyer’s patches in the terminal ileum. These intestinal lymphoid structures were continuously active and continuously producing galactose-deficient IgA1 as part of the chronic mucosal immune response that IgA nephropathy patients had year-round. This chronic intestinal production deposited IgA immune complexes in the mesangium every day, at a lower rate than the acute tonsillar bursts, without producing hematuria — the inflammatory response was below the threshold for vessel rupture and visible bleeding — but the deposits still activated complement and mesangial TGF-beta1 signaling, drove mesangial matrix expansion, and contributed to tubulointerstitial fibrosis. On a ten-year or twenty-year timescale, this chronic silent deposition was responsible for the progressive eGFR decline and ultimate nephron loss in IgA nephropathy, not the acute hematuria episodes themselves.
The targeted-release budesonide was designed specifically for this chronic intestinal source. The capsule did not dissolve in the stomach or the small intestine above the terminal ileum; it was engineered to dissolve in the alkaline environment of the terminal ileum, delivering budesonide directly to the Peyer’s patches. Budesonide is a corticosteroid that at this targeted low dose suppressed local plasmablast activation and reduced Gd-IgA1 production from these intestinal sites without the systemic steroid effects that would come from a systemic corticosteroid at the same dose. The NefIgArd trial had shown that nine months of this targeted-release budesonide reduced urine proteinuria by approximately forty percent and preserved eGFR compared to placebo over two years of follow-up — including patients who looked like Sofía, with relatively preserved kidney function, because the benefit was in slowing the chronic silent disease process. The absence of hematuria on treatment was partly because the drug was reducing the Gd-IgA1 background, which reduced the severity of the acute response when infections occurred — and this was good news. But it was not evidence that the disease had resolved; it was evidence that the drug was reducing the chronic production that drove both the acute exacerbations and the silent progressive nephron loss.
Sofía asked: “¿Y si dejo de tomar el medicamento y no me vuelve la sangre en la orina, eso significa que se curó?” (And if I stop taking the medication and the blood in the urine doesn’t come back, does that mean it was cured?) García-Ramos answered carefully: “No necesariamente. La sangre visible requiere un nivel muy alto de inflamación en el riñón — mucho más que el que ocurre todos los días de manera silenciosa. Puede que pare el medicamento y no vea sangre por meses, pero los depósitos siguen formándose en los filtros del riñón sin producir señal visible. El daño acumulado va apareciendo en la creatinina cinco o diez años después — cuando ya se perdieron bastantes filtros para que el número cambie. Por eso no usamos la sangre en la orina como la prueba de que el medicamento está funcionando o de que la enfermedad se curó — usamos la proteína en la orina y el eGFR, que son más sensibles a los cambios dentro del riñón.” (Not necessarily. Visible blood requires a very high level of inflammation in the kidney — much more than what occurs every day silently. It may be that you stop the medication and don’t see blood for months, but the deposits continue forming in the kidney filters without producing a visible signal. The accumulated damage appears in the creatinine five or ten years later — when enough filters have been lost for the number to change. That is why we do not use blood in the urine as the proof that the medication is working or that the disease was cured — we use protein in the urine and eGFR, which are more sensitive to changes inside the kidney.) Sofía agreed to continue the targeted-release budesonide and scheduled a conversation with Dr. Reyes-Torres about the full treatment duration plan. At the twelve-month assessment, proteinuria was 0.18 grams per gram and eGFR was 87 ml/min/1.73m² — stable to slightly improved from diagnosis.
Scenario 3: Marco Torres-Espinoza — 44 years old, Dallas, Texas
Marco Torres-Espinoza was a restaurant owner in Dallas with a seven-year history of IgA nephropathy diagnosed by kidney biopsy after a hypertensive crisis evaluation at age thirty-seven found protein in the urine. His biopsy at diagnosis had shown Oxford M1 E1 S1 T1 C0 — mesangial hypercellularity, endocapillary hypercellularity, segmental sclerosis, and mild tubular atrophy and interstitial fibrosis in less than twenty-five percent of the cortex, indicating established but not severe chronic damage. He had been on lisinopril twenty milligrams daily for seven years with partial proteinuria response — proteinuria had fallen from 1.6 grams per day at diagnosis to 0.9 grams per day on maximum-tolerated lisinopril. His creatinine at the most recent visit before the new medication was initiated was 1.4 milligrams per deciliter (eGFR 52 ml/min/1.73m²). His nephrologist initiated dapagliflozin ten milligrams daily at the most recent guideline update incorporating SGLT2 inhibitor evidence into IgA nephropathy management.
The response was clinically impressive. At six weeks, urine protein-to-creatinine ratio had fallen from 0.72 grams per gram (equivalent to 0.9 grams per day) to 0.37 grams per gram. At the three-month visit it was 0.33 grams per gram. At the six-month visit it was 0.31 grams per gram — the lowest protein level Marco had achieved in seven years of treatment. His blood pressure was well controlled at 124/76 millimeters of mercury. He felt well. He came to the six-month visit having already stopped dapagliflozin two weeks earlier. His explanation was direct and practical: the protein in the urine had fallen to less than half of what it had been before starting the medication, his kidney function number was stable, he felt the medication had accomplished what it was supposed to accomplish, and he was already on three other daily medications (lisinopril, fish oil, and a blood pressure medication) and was resistant to adding a fourth medication permanently when the kidney markers appeared to have improved. He also told his nurse, Roberto Cisneros-Vásquez, that he had read the drug was originally for diabetes and he was not diabetic.
Nurse Cisneros-Vásquez had encountered exactly this line of reasoning before: a patient who had achieved a meaningful improvement in a tracked biomarker and who, completely reasonably, interpreted the improvement as achievement of the treatment goal. He asked Marco if he could explain specifically what the dapagliflozin was doing for his kidneys — separate from the protein measurement — before they talked through the decision together.
Cisneros-Vásquez began with what the protein-in-urine number actually measured and what it did not measure. The protein level in the urine was a marker of how damaged the glomerular filtering membrane was — a leaky membrane let more protein through. The RAAS medications Marco had been taking for seven years had reduced some of this leakiness through both blood pressure reduction and direct anti-proteinuric mechanisms; the protein had fallen from 1.6 to 0.9 grams per day on lisinopril over seven years. The additional fall from 0.9 to 0.3 grams per day on dapagliflozin was excellent and did reflect better protection of the filtering membrane. But protein in the urine was not the only mechanism by which IgA nephropathy was damaging Marco’s kidneys, and the protein improvement did not mean all three of dapagliflozin’s protective mechanisms had done their job and could be discontinued.
The primary mechanism of dapagliflozin in the kidney, Cisneros-Vásquez explained, was correcting something called glomerular hyperfiltration. In Marco’s kidney, seven years of IgA nephropathy had damaged a substantial number of the kidney filters — the biopsy had shown segmental sclerosis in S1 and T1 tubular atrophy, meaning permanent damage had already occurred to some nephrons. The surviving nephrons were working harder to compensate, each one filtering more blood than it was designed for — a state called hyperfiltration. This excess pressure and flow through each remaining filter was itself damaging to those filters: it mechanically stressed the filter membrane and the cells supporting it, accelerating their injury over time. Dapagliflozin blocked a protein called SGLT2 in the proximal tubule of the kidney — a part of the kidney that was not the filter itself but the tube leading away from each filter. When SGLT2 was blocked, less sodium was absorbed from the kidney tubule, and more sodium reached a sodium-sensing region called the macula densa. The macula densa detected this sodium and sent a signal that constricted the blood vessel leading into the kidney filter, reducing the flow and pressure through that filter. This mechanism — called tubuloglomerular feedback restoration — operated entirely independently of how much protein was in the urine or what the blood pressure was. It was reducing the hyperfiltration pressure through the remaining filters every day the drug was taken, and allowing that pressure to return the day the drug was stopped.
There were two additional mechanisms that were also independent of the protein number. Inside the kidney tubule cells, blocking SGLT2 reduced glucose metabolism and forced the cells to use alternative energy sources. This metabolic shift reduced the production of inflammatory signals inside those cells — specifically reducing NF-kB activation, which was the master switch that produced IL-6, MCP-1, TGF-beta1, and other inflammatory cytokines from tubular cells into the surrounding kidney tissue. Lower inflammatory cytokine production from tubular cells meant less immune cell recruitment into the tubulointerstitium, and slower progression of interstitial fibrosis. A third mechanism involved something called the NLRP3 inflammasome — a cellular inflammatory machinery in tubular cells that dapagliflozin had been shown to suppress, reducing the production of IL-1beta from tubular cells. All three of these mechanisms — hyperfiltration correction, NF-kB suppression, NLRP3 inhibition — operated continuously while the drug was present and were absent the day the drug was stopped.
As for the point about diabetes, Cisneros-Vásquez acknowledged this directly. Dapagliflozin was developed originally for type 2 diabetes management, where its mechanism of increasing glucose excretion in the urine lowered blood glucose. But the kidney-protective mechanisms had been identified separately from the glucose effect, and clinical trials had been run specifically in people with kidney disease who did not have diabetes. The DAPA-CKD trial had enrolled patients with CKD from various causes including IgA nephropathy — specifically patients like Marco with reduced eGFR and proteinuria — and had demonstrated a twenty-nine percent reduction in the composite endpoint of kidney failure (GFR halving, end-stage kidney disease, or kidney death) in the IgA nephropathy subgroup. This benefit came through exactly the mechanisms described: hyperfiltration correction and tubular anti-inflammatory effects. The drug was now guideline-recommended for IgA nephropathy in patients with proteinuria above 0.5 grams per gram regardless of whether they had diabetes, because the benefit came from its kidney mechanisms, not its glucose mechanism.
Marco listened carefully and then asked: “¿Y si bajo la proteína a 0.3 gramos ya, qué tanto más puede bajar para justificar seguirlo tomando?” (And if I already lowered the protein to 0.3 grams, how much more can it fall to justify continuing to take it?) Cisneros-Vásquez answered: “El objetivo del medicamento no es bajar la proteína a un número específico — es mantener los tres efectos protectores activos. La proteína de 0.3 significa que esos efectos están funcionando. Si para el medicamento, la presión dentro de los filtros sube de nuevo en días a semanas, la proteína vuelve a 0.7 a 0.9 en pocas semanas, y la inflamación interna en los túbulos que estaba siendo suprimida se reanuda. El número 0.3 que ve en el papel no es la enfermedad en ese nivel — es el medicamento activo produciendo ese resultado. Sin el medicamento, la enfermedad vuelve al nivel que tenía antes.” (The goal of the medication is not to lower the protein to a specific number — it is to keep the three protective effects active. The protein of 0.3 means those effects are working. If you stop the medication, the pressure inside the filters rises again within days to weeks, the protein returns to 0.7 to 0.9 within a few weeks, and the internal inflammation in the tubules that was being suppressed resumes. The 0.3 number you see on the paper is not the disease at that level — it is the active medication producing that result. Without the medication, the disease returns to the level it had before.) Marco agreed to restart dapagliflozin that afternoon. He was given written materials explaining each of his four medications and their specific mechanisms in IgA nephropathy. At the nine-month visit — three months after restarting — proteinuria was 0.30 grams per gram, identical to the pre-cessation value, confirming the rapid return to protection. Creatinine was 1.4 mg/dL, unchanged from before dapagliflozin initiation — consistent with GFR preservation through the trial period.
Frequently asked questions
How do IgA nephropathy clinic nurses explain why RAAS blockade must continue even after creatinine has normalized and proteinuria has fallen substantially?
RAAS blockade provides nephron protection in IgA nephropathy through three mechanisms that are all independent of the creatinine number and active only while the drug is present. The first is hemodynamic: angiotensin II constricts the efferent arteriole disproportionately compared to the afferent arteriole, raising intraglomerular hydraulic pressure above systemic pressure, which mechanically stresses the remaining glomeruli and accelerates their injury; ACE inhibitor or ARB blockade reduces this efferent arteriolar tone and lowers intraglomerular pressure independent of whether systemic blood pressure is elevated. The second is anti-fibrotic: angiotensin II directly stimulates TGF-beta1 production in mesangial cells through AT1 receptor-NF-kB signaling; TGF-beta1 drives mesangial matrix expansion and tubulointerstitial fibrosis; RAAS blockade reduces this TGF-beta1 signal independent of blood pressure. The third is protection from tubular injury: proteinuria causes direct tubular cell injury through megalin-cubilin uptake of filtered protein overwhelming lysosomal degradation, activating NF-kB in tubular cells and driving interstitial fibrosis; RAAS blockade reduces the proteinuria load on tubular cells through hemodynamic and direct anti-albuminuric mechanisms. Creatinine normalization reflects the hemodynamic protection of surviving nephrons working well — not resolution of the ongoing Gd-IgA1 immune complex deposition. Stopping RAAS blockade allows intraglomerular pressure to increase within days, proteinuria to return toward pre-treatment levels within two to four months, and progressive nephron loss to resume. The Spanish frame: “La creatinina normal significa que el medicamento está protegiendo bien lo que le queda de riñón — no que la enfermedad que estaba dañando el riñón desapareció. Si para el medicamento, la presión dentro de los filtros sube, la proteína vuelve, y el proceso de daño se reanuda aunque no lo sienta.” (The normal creatinine means the medication is protecting what remains of the kidney well — not that the disease damaging the kidney disappeared. If you stop the medication, the pressure inside the filters rises, the protein returns, and the damage process resumes even though you do not feel it.)
How do IgA nephropathy clinic nurses explain why targeted-release budesonide must continue even when gross hematuria episodes have stopped for months?
Gross hematuria in IgA nephropathy results from acute surges of galactose-deficient IgA1 from tonsillar plasmablasts during upper respiratory infections, producing rapid mesangial immune complex deposition severe enough to rupture glomerular capillaries and produce visible bleeding. Targeted-release budesonide suppresses Gd-IgA1 production in ileal Peyer’s patches, reducing both the chronic background deposition and the severity of acute infection-triggered exacerbations. When hematuria episodes stop, this reflects reduced acute Gd-IgA1 surges — not resolution of the chronic intestinal Gd-IgA1 production that deposits immune complexes in the mesangium every day without producing visible hematuria. The NefIgArd trial demonstrated that nine months of targeted-release budesonide reduced proteinuria forty percent and slowed eGFR decline versus placebo in patients across all hematuria-activity categories. Stopping budesonide removes suppression of ileal Gd-IgA1 production, allowing the chronic background deposition that drives Oxford M1 mesangial hypercellularity progression and tubulointerstitial fibrosis to resume at pre-treatment rates. The Spanish frame: “Los episodios de sangre son la manifestación aguda de la enfermedad. El daño que avanza día a día en silencio — sin sangre visible — viene de la producción continua de la misma proteína anormal en el intestino. El medicamento actúa principalmente ahí. Que no haya sangre visible es señal de que funciona — no de que la enfermedad se curó.” (The blood episodes are the acute manifestation of the disease. The damage that advances day by day silently — without visible blood — comes from the continuous production of the same abnormal protein in the intestine. The medication acts primarily there. The absence of visible blood is a sign that it is working — not that the disease was cured.)